Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject participated in study C87085 \[NCT00552058\] in which the subject completed the study at Week 6~* Subject is capable of providing informed consent, which must be obtained prior to any study related procedures~* Have a chest X-ray taken at Visit 1 that is read by a qualified radiologist or pulmonary physician, with no evidence of current active Tuberculosis (TB) or old inactive TB~* Subject has taken a TB survey and is committed to comply with TB prophylaxis if applicable~Exclusion Criteria:~* Subject is experiencing an ongoing serious adverse event assessed as being related to study medication or is experiencing a serious adverse event that is still not assessable~* Subject has an intercurrent illness that requires termination of treatment, such as a serious infection (e.g. TB, pneumonia, sepsis, pyelonephritis, fistula abscess)~* Subject is non-compliant with TB prophylactic treatment (if applicable)~* Subject has had a chest X-ray at Visit 1 that shows an abnormality suggestive of a malignancy or active infection, including TB~* Female who is pregnant or breast feeding~* Female of child bearing age or post puberty males not practicing effective birth control~* Subject is expecting to receive any live virus or bacterial vaccination within 3 months of first Study Medication administration, during the trial or 3 months after last dose of study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Certolizumab Pegol (Type: EXPERIMENTAL): Certolizumab Pegol 200 mg/vial; 400 mg subcutaneously at Week 0, 2 and 4, thereafter 400 mg subcutaneously at every 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).